About Compass Therapeutics
Compass Therapeutics is a company based in Cambridge (United States) founded in 2013. Compass Therapeutics has raised $238.46 million across 5 funding rounds from investors including BioMed Realty, TD Securities and Orbimed. The company has 35 employees as of December 31, 2024. Compass Therapeutics has completed 1 acquisition, including TRIGR Therapeutics. Compass Therapeutics offers products and services including COMPANION-002, COMPANION-003, CTX-471, and CTX-8371. Compass Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 35 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Compass Therapeutics, Inc.
-
Annual Revenue
$850 K (USD)0as on Dec 31, 2024
-
Net Profit
-$49.38 M (USD)-16.19as on Dec 31, 2024
-
EBITDA
-$54.87 M (USD)-13.2as on Dec 31, 2024
-
Total Equity Funding
$238.46 M (USD)
in 5 rounds
-
Latest Funding Round
$60.48 M (USD), Series A
Jun 23, 2020
-
Investors
BioMed Realty
& 11 more
-
Employee Count
35
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Compass Therapeutics
Compass Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CMPX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Compass Therapeutics
Compass Therapeutics offers a comprehensive portfolio of products and services, including COMPANION-002, COMPANION-003, CTX-471, and CTX-8371.
Trial for first-line treatment of biliary tract cancer using antibodies.
Trial advancing cancer therapies through immune response optimization.
Antibody therapy combined with KEYTRUDA for cancer treatment.
Product candidate targeting tumor microenvironment in oncology.
People of Compass Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Compass Therapeutics
Compass Therapeutics has successfully raised a total of $238.46M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $60.48 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Compass Therapeutics
Compass Therapeutics has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include BioMed Realty, TD Securities and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in seed & series A startups
|
Locked | Locked | Locked |
Investor details for Compass Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Compass Therapeutics
Compass Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include TRIGR Therapeutics.
Investment portfolio details for Compass Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics for cancer are developed by the company.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Compass Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Compass Therapeutics
Detailed financials for Compass Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Compass Therapeutics Comparisons
Peer comparison for Compass Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Compass Therapeutics
Compass Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Compass Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Compass Therapeutics
Complete news archive for Compass Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Compass Therapeutics
Compass Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Compass Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Compass Therapeutics is a funded company, having raised a total of $238.46M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Compass Therapeutics is 35.
Annual revenue of Compass Therapeutics is $850K as on Dec 31, 2024.
Compass Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Operations center on the discovery and development of therapeutic antibodies targeting cancer. Focus is placed on combinations of human monoclonal antibodies, multiclonal mixtures, and engineered protein constructs to address the tumor-immune synapse. The company operates within the biotechnology sector, emphasizing oncology applications.
Compass Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Compass Therapeutics offers COMPANION-002, COMPANION-003, CTX-471, and CTX-8371.
Yes, Compass Therapeutics is publicly traded on NASDAQ under the ticker symbol CMPX.
Compass Therapeutics has made 1 acquisition, including TRIGR Therapeutics.
Compass Therapeutics has 12 investors. Key investors include BioMed Realty, TD Securities, Orbimed, F-Prime Capital, and Borealis Ventures.
The ticker symbol of Compass Therapeutics is CMPX on NASDAQ.